VEGFR-2 inhibitor, also known as kinase insert domain receptor(KDR) inhibitor, are tyrosine kinase receptor inhibitors that reduce angiogenesis or lymphangiogenesis...
51 KB (4,735 words) - 08:15, 2 January 2024
A protein kinase inhibitor (PKI) is a type of enzyme inhibitor that blocks the action of one or more protein kinases. Protein kinases are enzymes that...
23 KB (750 words) - 23:26, 13 August 2024
ester of a VEGFR-2 inhibitor BMS-540215 and is hydrolyzed to the active moiety BMS-540215 in vivo. BMS-540215, a dual tyrosine kinase inhibitor, shows potent...
12 KB (1,277 words) - 07:01, 2 December 2023
VEGF receptor (redirect from VEGFR inhibitor)
alternative splicing, they may be membrane-bound (mbVEGFR) or soluble (sVEGFR). Inhibitors of VEGFR are used in the treatment of cancer. Vascular endothelial...
8 KB (754 words) - 13:03, 18 September 2024
Foretinib (category Tyrosine kinase inhibitors)
kinase inhibitor with FDA approval VEGFR inhibitor tyrosine-kinase inhibitor Hedgethorne, K.; Huang, P.H. (2010). "Foretinib. c-Met and VEGFR-2 inhibitor, Oncolytic"...
4 KB (183 words) - 09:39, 5 September 2024
Strategies to inhibit the VEGF pathway include antibodies directed against VEGF or VEGFR, soluble VEGFR/VEGFR hybrids, and tyrosine kinase inhibitors. The most...
33 KB (3,229 words) - 19:54, 7 July 2024
to bind RET specifically, these inhibitors have other targets such as VEGFR, c-MET, and c-KIT. Among them, the VEGFR-related toxicities commonly precluded...
20 KB (2,041 words) - 12:05, 3 October 2024
Kinase insert domain receptor (redirect from VEGFR-2)
tyrosine kinase) also known as vascular endothelial growth factor receptor 2 (VEGFR-2) is a VEGF receptor. KDR is the human gene encoding it. KDR has also been...
6 KB (794 words) - 11:50, 18 May 2022
receptors of epidermal cells (EGFR inhibitors) and those that target vascular endothelial growth factor receptors (VEGFR inhibitors). In cancer treatment, growth...
4 KB (381 words) - 22:35, 2 December 2023
Decoy receptors (section VEGFR-1)
VEGFR-1 is required for normal development and angiogenesis. VEGFR-1 inhibits the activity of VEGFR-2 by sequestering VEGF, thus preventing VEGFR-2 from...
6 KB (686 words) - 02:37, 26 February 2022
expression of ANG2, bFGF, PDGF, VEGF, and VEGFR. Inhibition of HIF1α translation by preventing PDGF/PDGFR and VEGF/VEGFR can result from mTOR inhibition. A G0-G1...
57 KB (6,280 words) - 19:28, 19 September 2024
Nintedanib (category Tyrosine kinase inhibitors)
fibroblast growth factor receptor (FGFR) 1, 2, and 3; vascular endothelial growth factor receptor (VEGFR) 1, 2, and 3; and FLT3. Its use in IPF is predicated...
34 KB (3,021 words) - 12:39, 5 August 2024
a dasatinib analog or a novel way to inhibit TKs. Rebastinib (DCC-2036) Also an inhibitor of TIE-2 and VEGFR-2. It has had a phase 1 clinical trial for...
56 KB (6,470 words) - 06:03, 24 October 2024
A CDK (cyclin-dependent kinase) inhibitor is any chemical that inhibits the function of CDKs. They are used to treat cancers by preventing overproliferation...
24 KB (2,633 words) - 00:57, 22 April 2024
Receptor tyrosine kinase (redirect from EC 2.7.10.1)
to VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). VEGFR-2 appears to mediate almost all of the known cellular responses to VEGF. The function of VEGFR-1 is...
28 KB (3,078 words) - 07:46, 3 June 2024
Tivozanib (category Angiogenesis inhibitors)
Bolos J, Castaner R (October 2009). "Tivozanib VEGFR Tyrosine Kinase Inhibitor Angiogenesis Inhibitor Oncolytic". Drugs of the Future. 34 (10): 793–6...
15 KB (1,189 words) - 10:58, 19 June 2024
peptidase-4 inhibitor and prolyl oligopeptidase inhibitor at high concentrations (in the millimolar range). It is an effective inhibitor in laboratory...
9 KB (857 words) - 17:24, 18 July 2024
Pazopanib (category Receptor tyrosine kinase inhibitors)
inhibitor that limits tumor growth by targeting angiogenesis via inhibition of enzymes including vascular endothelial growth factor receptor (VEGFR)...
16 KB (1,322 words) - 22:43, 12 September 2024
Vatalanib (category Angiogenesis inhibitors)
Novartis. It inhibits all known VEGF receptors, as well as platelet-derived growth factor receptor-beta and c-kit, but is most selective for VEGFR-2. Vatalanib...
7 KB (564 words) - 16:04, 9 January 2024
include growth factor inhibitors, endogenous angiogenesis inhibitors, fumagillin analogues, statins, cyclo-oxygenase-2 inhibitors, phytochemical compounds...
154 KB (16,258 words) - 10:19, 22 October 2024
team discovered that inhibiting a key player in the signaling system (called vascular endothelial growth factor receptor or VEGFR) suppresses the generation...
9 KB (913 words) - 05:31, 5 August 2024
vascular endothelial growth factor (VEGF) from binding to the VEGFR-2 The TNF inhibitor etanercept exerts its anti-inflammatory effect by being a decoy...
12 KB (1,373 words) - 15:37, 15 September 2024
Alzheimer's. The company sold the rights to Faldaprevir, a HCV protease inhibitor to Trek Therapeutics. In July 2016, the company sold the commercialisation...
40 KB (3,323 words) - 14:28, 25 October 2024
(BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin". Clinical Cancer Research. 17 (2): 363–71. doi:10.1158/1078-0432...
5 KB (348 words) - 01:45, 30 May 2023
Surufatinib (category Kinase inhibitors)
et al. (2014). "First-in-human (FIH) phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid...
5 KB (229 words) - 06:02, 5 July 2024
to VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). VEGFR-2 appears to mediate almost all of the known cellular responses to VEGF. The function of VEGFR-1 is...
40 KB (4,578 words) - 12:30, 10 September 2024
factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases". EMBO J. 15 (2): 290–298. doi:10.1002/j.1460-2075.1996.tb00359...
24 KB (2,882 words) - 16:31, 25 October 2024
also pioneered the inhibitors of EGF receptor, PDGF receptor, Her-2/neu, Jak-2, VEGFR and peptide based cell permeable PKB/Akt inhibitors. Levitzki also showed...
10 KB (902 words) - 17:38, 22 July 2024
Ramucirumab (category Angiogenesis inhibitors)
to the extracellular domain of VEGFR2 and block the binding of natural VEGFR ligands (VEGF-A, VEGF-C and VEGF-D). These ligands are secreted by solid...
16 KB (1,399 words) - 03:46, 22 October 2024
received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. The...
12 KB (821 words) - 02:57, 12 October 2024